Genentech Licenses BioInvent's Cardiovascular Drug Candidate
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on January 15, 2007
Genentech, Inc. is paying an upfront payment of $15 million to co-develop and commercialize BioInvent´s proprietary antibody candidate, BI-204, for the potential treatment of multiple cardiovascular conditions. In addition, BioInvent could receive further milestone payments of up to $175 million as well as royalties on sales in North America.
BI-204 is developed to prevent atherosclerosis and myocardial infarction by blocking a major mediator of vascular inflammation that is believed to lead to the formation of unstable plaque in the vessel wall.
Source: BioInvent
Tags: cardiovascular+disease athersclerosis myocardial+infarct Genentech BioInvent biotech drug+candidate
Vote for Genentech Licenses BioInvent's Cardiovascular Drug Candidate:
|
Rating: 9.25 out of 4 vote(s) cast.
|
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells